TG Therapeutics, Inc.

NasdaqCM:TGTX Stock Report

Market Cap: US$2.3b

TG Therapeutics Balance Sheet Health

Financial Health criteria checks 3/6

TG Therapeutics has a total shareholder equity of $160.5M and total debt of $100.5M, which brings its debt-to-equity ratio to 62.6%. Its total assets and total liabilities are $329.6M and $169.1M respectively. TG Therapeutics's EBIT is $20.6M making its interest coverage ratio 1.6. It has cash and short-term investments of $217.5M.

Key information

62.6%

Debt to equity ratio

US$100.48m

Debt

Interest coverage ratio1.6x
CashUS$217.51m
EquityUS$160.50m
Total liabilitiesUS$169.09m
Total assetsUS$329.59m

Recent financial health updates

Recent updates

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Jan 04
Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Nov 24
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Sep 30
TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Aug 03
Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jul 19
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Apr 13
Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Jan 02
Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

TG Therapeutics: Elucidating The Upcoming Binary

Oct 09

TG Therapeutics: We Are Just Hanging In There

Sep 21

Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

Sep 07
Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials

Aug 25

TG Therapeutics Q2 2022 Earnings Preview

Aug 05

TG Therapeutics And Ublituximab: From Icing To Lifeline

Jul 08

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jun 06
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

TG Therapeutics: I May Double Down Again

Apr 18

Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe

Feb 08

TG Therapeutics: Double Down On Partial Clinical Hold Non-Issue

Jan 28

TG Therapeutics: Elucidating The Upcoming Binary Event

Dec 27

Financial Position Analysis

Short Term Liabilities: TGTX's short term assets ($317.9M) exceed its short term liabilities ($53.7M).

Long Term Liabilities: TGTX's short term assets ($317.9M) exceed its long term liabilities ($115.4M).


Debt to Equity History and Analysis

Debt Level: TGTX has more cash than its total debt.

Reducing Debt: TGTX's debt to equity ratio has increased from 0.3% to 62.6% over the past 5 years.

Debt Coverage: TGTX's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: TGTX's interest payments on its debt are not well covered by EBIT (1.6x coverage).


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.